GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Meta] proposal — a flair for STEP posts — 35 comments in the full submission. View in context.
4.7k
c/trialwatch·submitted 2 years ago by u/foam_head_fred

[Meta] proposal — a flair for STEP posts

Paperbranch of 10 comments

Week 73 update. 19kg down from the start, early fullness basically gone since about week 30. Things that worked: consistency, protein at breakfast, walking more than I want to. Things that did not: everything I bought on the internet to help with early fullness. The part that surprised me is how much of this is…

Read the full submission and all 35 comments →

This branch

10 comments, started 2 years ago
u/hedda_adeyemi176 points·2 years ago

phase 2 is not phase 3, smaller n and shorter trial

replysharereportpermalink
u/slow_logbook_notes30135 points·2 years ago

Disagree but this is the good kind of wrong — it is specific enough to be checked.

replysharereportpermalink
u/karl_fischer_kev59 points·2 years ago

the relative risk reduction in headlines is not the whole story

replysharereportpermalink
u/foam_head_fredOP77 points·2 years ago

Strongly agree. Phase 2 is investigational, not conclusive.

replysharereportpermalink
[deleted]28 points·2 years ago

[deleted]

replysharereportpermalink
u/eu_apotheke_a69 points·2 years ago

What was the dropout rate?

replysharereportpermalink
u/bastian_ekstrom136 points·2 years ago

event rates are more informative than hazard ratios alone

replysharereportpermalink
u/nightowl_injector40 points·2 years ago

the 21 week readout is different from the 27 week readout

replysharereportpermalink
u/rina_sobczak102 points·2 years ago

give the trial name, phase, n, and primary endpoint in the body

replysharereportpermalink
u/enzo_ferrari84 points·2 years ago

the relative risk reduction in headlines is not the whole story

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →